NYR 3.51% 5.9¢ nyrada inc.

Ann: Significant Neuroprotection in NYR Preclinical Brain Injury, page-186

  1. 10,171 Posts.
    lightbulb Created with Sketch. 1982
    It’s funny that they are fully funded all the way into phase 2 with non dilutive funding extending the companies funds well into phase 2 and the market cap is now trading below it’s coming up cash funding pricing nothing in for how de risked the drug is heading into phase 1 and phase 2 FDA approval. AGN is looking like on any good news will become a 200-300 million dollar company on the potential of the drug.
 
watchlist Created with Sketch. Add NYR (ASX) to my watchlist
(20min delay)
Last
5.9¢
Change
0.002(3.51%)
Mkt cap ! $10.75M
Open High Low Value Volume
5.8¢ 5.9¢ 5.7¢ $6.913K 120.7K

Buyers (Bids)

No. Vol. Price($)
1 6000 5.6¢
 

Sellers (Offers)

Price($) Vol. No.
6.0¢ 7000 1
View Market Depth
Last trade - 15.16pm 28/06/2024 (20 minute delay) ?
NYR (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.